BRCA2 and cancer: Previous studies have shown that RAD52 is required for viability of BRCA1- and BRCA2-deficient cells [22,23], suggesting a targeted treatment opportunity via inhibition of RAD52 to specifically kill cancer cells with BRCA deficiency.